Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men

Details

• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR)
• Personal Author:
  Smith, Dawn K. ; Grant, Robert M. ; Weidle, Paul J. ; Lansky, Amy ; Mermin, Jonathan ; Fenton, Kevin A.
• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.)
• Description:
  An estimated 56,000 human immunodeficiency virus (HIV) infections occur each year in the United States. Men who have sex with men (MSM) account for 53% of the estimated incident infections, and surveillance data suggest that the annual number of new HIV infections among MSM has been rising since the mid-1990s. Strategies for reducing acquisition of HIV infection by MSM have included 1) expanded HIV testing so that infected persons can be treated and their risk for transmitting infection minimized; 2) individual, small-group, and community-level behavioral interventions to reduce risk behaviors; 3) promotion of condom use; 4) detection and treatment of sexually transmitted infections; and 5) mental health and substance abuse counseling when needed. On November 23, 2010, investigators for the Pre-Exposure Prophylaxis Initiative (iPrEX) study announced results from a multinational, randomized, double-blind, placebo-controlled, phase III clinical trial of daily oral antiretrovirals (tenofovir disoproxil fumarate [TDF] and emtricitabine [FTC]) to prevent acquisition of HIV infection among uninfected but exposed MSM. This report provides interim guidance to health-care providers based on the reported results of that trial, which indicated that TDF plus FTC taken orally once a day as preexposure prophylaxis (PrEP) is safe and partially effective in reducing HIV acquisition among MSM when provided with regular monitoring of HIV status and ongoing risk-reduction and PrEP medication adherence counseling.
• Subjects:
  Adenine/administration & Dosage Adenine/analogs & Derivatives Antiviral Agents/therapeutic Use Deoxycytidine/administration & Dosage Deoxycytidine/analogs & Derivatives Double-Blind Method Drug Therapy, Combination HIV Infections/prevention & Control Homosexuality, Male Humans Male Organophosphonates/administration & Dosage Unsafe Sex

  More +
• Source:
  MMWR. Morbidity and mortality weekly report. 2011 Jan 28; 60(3):65-68.
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Pubmed ID:
  21270743
• Document Type:
  Journal Article
• Genre:
  Practice Guideline
• Place as Subject:
  United States
• Pages in Document:
  4 pdf pages
• Volume:
  60
• Issue:
  3
• Collection(s):
  Guidelines and Recommendations Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:6038ddf1512e9aaca7b5ae762db758f22aba44849d5c6d77a4ac432a26479f955700e2947d182d614502e48fad79813c59a43334bd28c200e98b3b5b1045d088
• Download URL:
  https://stacks.cdc.gov/view/cdc/23106/cdc_23106_DS1.pdf
• File Type:
  [PDF - 151.29 KB ]